What is Selkirk Pharma?
Selkirk Pharma operates as a specialized contract manufacturing organization (CMO) focused on aseptic fill and finish services. The company distinguishes itself through a purpose-built, state-of-the-art facility designed to optimize production efficiency for critical pharmaceutical products. By integrating advanced SKAN isolator technology and high-yield Bausch & Stroebel filling equipment, Selkirk Pharma ensures unidirectional process flows that meet rigorous regulatory standards. This infrastructure allows the firm to serve as a reliable partner for biopharmaceutical companies requiring precision manufacturing to address complex patient needs in a competitive global market.
How much funding has Selkirk Pharma raised?
Selkirk Pharma has raised a total of $33M across 2 funding rounds:
Angel/Seed
$9M
Angel/Seed
$24M
Angel/Seed (2020): $9M, investors not publicly disclosed
Angel/Seed (2023): $24M, investors not publicly disclosed
Key Investors in Selkirk Pharma
Selkirk Pharma
Undisclosed investor participating in the funding round.
Selkirk Pharma
Undisclosed investor participating in the funding round.
Selkirk Pharma
Undisclosed investor participating in the funding round.
What's next for Selkirk Pharma?
With the recent infusion of capital, Selkirk Pharma is positioned to accelerate its operational scaling and enhance its service offerings within the aseptic manufacturing landscape. The company's strategic roadmap likely involves expanding its vial capacity and further refining its high-yield production methodologies to accommodate a broader range of complex biologics. As the pharmaceutical industry continues to emphasize supply chain resilience and localized manufacturing, Selkirk Pharma's focus on advanced facility design and process integrity provides a robust foundation for long-term growth and market leadership in the contract manufacturing space.
See full Selkirk Pharma company page
